Growth-differentiation factor-15 and major cardiac events

American Journal of the Medical Sciences

Volumn 347, Issue 4, 2014, Pages 305-311

  Lin, Jeng Feng ^a,b   Wu, Semon ^a,d   Hsu, Shun Yi ^a,b   Yeh, Kuan Hung ^a,b   Chou, Hsin Hua ^a   Cheng, Shih Tsung ^a   Wu, Tien Yu ^a   Hsu, Wen Tze ^a   Yang, Chun Chun ^c   Ko, Yu Lin ^a,b  

^a Taipei Branch   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d CHINESE CULTURE UNIVERSITY   (Taiwan)

Author keywords

Acute myocardial infarction; GDF 15; Left ventricular remodeling; N terminal pro B type natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GROWTH DIFFERENTIATION FACTOR 15;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; BIOLOGICAL MARKERS; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 84897114520     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318291cd4e     Document Type: Article

References (35)

1. White HD, Norris RM, Brown MA, et al. Left ventricular endsystolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51
2. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-12
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990;81:1161-72
4. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-Term prognostic implications. Circulation 2002;106: 2351-7
5. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 1994;89:68-75
6. Richards AM, Nicholls MG, Espiner EA, et al. B-Type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92
7. Najar RA, Ghaderian SM, Panah AS, et al. Association of transforming growth factor-b1 gene polymorphisms with genetic susceptibility to acute myocardial infarction. Am J Med Sci 2011;342: 365-70
8. Li XJ, Wang XW, Du YJ. Protective effects of erythropoietin on myocardial infarction in rats: The role of AMP-Activated protein kinase signaling pathway. Am J Med Sci 2011;342:153-9
9. Kempf T, Eden M, Strelau J, et al. The transforming growth factorbeta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-60
10. Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: A nested case-control study. Lancet 2002;359:2159-63
11. Wollert KC, Kempf T, Lagerqvist B, et al. Growth-differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome. Circulation 2007;116:1540-8
12. Eggers KM, Kempf T, Lagerqvist B, et al. Growth-differentiation factor-15 for long-Term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 2010;3:88-96
13. Eitel I, Blase P, Adams V, et al. Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: Insights from cardiovascular magnetic resonance. Heart 2011;97:632-40
14. Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009;30:1057-65
15. Hsu SY, Lin JF, Chang SH. Right ventricular function in patients with different infarction sites after a first acute myocardial infarction. Am J Med Sci 2011;342:474-9
16. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr 2005;18:1440-63
17. Savoye C, Equine O, Tricot O, et al. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol 2006;98:1144-9
18. Kempf T, Bjorklund E, Olofsson S, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007;28:2858-65
19. Lind L, Wallentin L, Kempf T, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: Results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009;30: 2346-53
20. Kempf T, Sinning JM, Quint A, et al. Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease results from the atherogene study. Circ Cardiovasc Genet 2009;2:286-92
21. Schlittenhardt D, Schober A, Strelau J, et al. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 2004; 318:325-33
22. Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res 2006;98:294-7
23. Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011;17:581-8
24. Taddei S, Virdis A. Growth differentiation factor-15 and cardiovascular dysfunction and disease: Malefactor or innocent bystander? Eur Heart J 2010;31:1168-71
25. Schiegnitz E, Kämmerer PW, Koch FP, et al. GDF 15 as an antiapoptotic, diagnostic and prognostic marker in oral squamous cell carcinoma. Oral Oncol 2012;48:608-14
26. Staff AC, Bock AJ, Becker C, et al. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 2010;118: 237-43
27. Zimmers TA, Gutierrez JC, Koniaris LG. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. J Cancer Res Clin Oncol 2010;136:571-6
28. Shin SY, Kim JH, Lee JH, et al. 2'-Hydroxyflavanone induces apoptosis through Egr-1 involving expression of Bax, p21, and NAG-1 in colon cancer cells. Mol Nutr Food Res 2012;56:761-74
29. Tsui KH, Chang YL, Feng TH, et al. Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells. J Mol Endocrinol 2012;49:153-63
30. Griner SE, Joshi JP, Nahta R. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochem Pharmacol 2013;85:46-58
31. Wang F, Guo Y, Yu H, et al. Growth differentiation factor 15 in different stages of heart failure: Potential screening implications. Biomarkers 2010;15:671-6
32. Santhanakrishnan R, Chong JP, Ng TP, et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-Terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012;14:1338-47
33. Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 2004;43:2022-7
34. McNamara RL, Wang Y, Herrin J, et al. Effect of door-To-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2006;47:2180-6
35. Minutello RM, Kim L, Aggarwal S, et al. Door-To-balloon time in primary percutaneous coronary intervention predicts degree of myocardial necrosis as measured using cardiac biomarkers. Tex Heart Inst J 2010;37:161-5